On the 30 June 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,394 million and NAV per share was SEK 39.14. Return on NAV* in the month was -2.1%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 4.01 | 10.3% |
| Prokarium | 50% | 287 | 3.31 | 8.5% |
| KAHR Medical | 34% | 209 | 2.41 | 6.2% |
| Empros Pharma | 79% | 204 | 2.36 | 6.0% |
| Atrogi | 44% | 197 | 2.27 | 5.8% |
| Bonsai Biotherapeutics | 100% | 158 | 1.82 | 4.6% |
| Microbiotica | 10% | 129 | 1.48 | 3.8% |
| Xspray Pharma | 17% | 119 | 1.38 | 3.5% |
| Xintela | 60% | 102 | 1.17 | 3.0% |
| Mendus | 23% | 81 | 0.94 | 2.4% |
| AnaCardio | 13% | 79 | 0.92 | 2.3% |
| Geneos Therapeutics | 12% | 70 | 0.80 | 2.1% |
| Vitara Biomedical | 11% | 55 | 0.63 | 1.6% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.63 | 1.6% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.38 | 1.0% |
| Egetis Therapeutics | 1% | 29 | 0.33 | 0.8% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.3% |
| Strike Pharma | 18% | 11 | 0.12 | 0.3% |
| Total | 2,177 | 25.12 | 64.2% | |
| Commercial Growth | ||||
| Symcel | 30% | 204 | 2.36 | 6.0% |
| NorthX Biologics | 61% | 202 | 2.33 | 5.9% |
| Chromafora | 28% | 137 | 1.59 | 4.1% |
| Nanologica | 50% | 79 | 0.91 | 2.3% |
| Frontier Biosolutions | 2% | 27 | 0.31 | 0.8% |
| Bohus Biotech | 45% | 22 | 0.26 | 0.7% |
| Total | 672 | 7.75 | 19.8% | |
| Assets related to Portfolio companies | 237 | 2.74 | 7.0% | |
| Other assets and liabilities | 307 | 3.54 | 9.1% | |
| Net Asset Value | 3,394 | 39.14 | 100.0% | |
* Following the bonus issue of 11,888,785 shares conducted in May and followed by a cancellation of 8,412,578 shares in June, the return for the month is calculated on total NAV instead of as previously NAV per share.